$16B Michigan Data Center Project Boosts U.S. AI Infrastructure Expansion 
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
Why Global Web3 Projects Can't Afford to Skip South Korea: TokenPost Unveils Data-Driven Entry Solutions 
Florida Launches Criminal Probe Into OpenAI Over FSU Shooting Incident 
SK Hynix Reports Record Q1 Profit Surge Driven by AI Memory Chip Demand 
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
Meta Expands AI Training With Employee Activity Tracking Tools 
Tesla Earnings Beat Expectations as EV Growth Holds Amid Robotics and AI Shift 
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review 
Elon Musk Signals Intel 14A Chips for Tesla’s Terafab AI Semiconductor Venture 
Amazon Stock Rises as Meta Expands AWS Partnership for AI Infrastructure 
U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
Kakaku.com Stock Surges on EQT Takeover Interest Amid Rising Japan Deal Activity 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
WALTHAM, Mass., March 02, 2016 -- Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class pharmaceuticals to address the medical needs of patients with kidney and vascular diseases, announced today that Company management will present at the Cowen and Company 36th Annual Health Care Conference in Boston on Tuesday, March 8, 2016, at 8:40 am ET.
About Proteon Therapeutics
Proteon Therapeutics is committed to improving the health of patients with kidney and vascular diseases through the development of novel, first-in-class therapeutics. Proteon’s lead product candidate, vonapanitase (formerly PRT-201), is an investigational drug intended to improve arteriovenous fistula (AVF) patency, the period of time during which an AVF remains open with adequate blood flow to enable hemodialysis. Proteon is currently evaluating vonapanitase in two Phase 3 clinical trials in patients with chronic kidney disease (CKD) undergoing surgical creation of a radiocephalic AVF for hemodialysis and has completed a Phase 1 clinical trial in patients with symptomatic peripheral artery disease (PAD). For more information, please visit www.proteontherapeutics.com.
Investor Contact
George Eldridge, Senior Vice President and Chief Financial Officer
781-890-0102
[email protected]
Press Contact
Chris Erdman, MacDougall Biomedical Communications
781-235-3060
[email protected]
